Last reviewed · How we verify

Tonghua Dongbao Pharmaceutical Co.,Ltd — Portfolio Competitive Intelligence Brief

Tonghua Dongbao Pharmaceutical Co.,Ltd pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Xultophy® Xultophy® marketed
THDB0206 injection THDB0206 injection phase 3

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Tonghua Dongbao Pharmaceutical Co.,Ltd:

Cite this brief

Drug Landscape (2026). Tonghua Dongbao Pharmaceutical Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tonghua-dongbao-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related